Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Chief Operating Officer | September 03, 2022 | September 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date September 03, 2022 · Filed September 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,710 |
Reported balance
After 2022-09-03 transaction · row 1
1 source rowRow 1 · 2022-09-03 · Tax withholding · Disposed 1,511 · Balance 10,710 F1: Reflects the number of shares of the issuers Common Stock that were withheld to cover tax liability in connection with vesting and settlement of restricted stock units reported on a prior Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the number of shares of the issuers Common Stock that were withheld to cover tax liability in connection with vesting and settlement of restricted stock units reported on a prior Form 4.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MANNKIND CORP
Report date July 15, 2025 · Filed July 18, 2025
Section 16 reporting ended · disclosed 2025-07-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 349,841 |
Reported balance
After 2025-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-07-15 · Tax withholding · Disposed 11,896 · Balance 349,841 F1: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. F2: Includes 3,888 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F2: Includes 3,888 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2025 Filed Jul 18, 2025 00:45 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 11,896 | $3.85 | $45,799.60 |
DisclosureSEC source: 0000950170-25-096736 · ownership.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,841 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. F2 · balance_after: Includes 3,888 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025. Read SEC document |
| March 27, 2025 Filed Mar 29, 2025 00:20 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 16,407 | $5.10 | $83,675.70 |
DisclosureSEC source: 0000950170-25-047092 · ownership.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 357,849 F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:50 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 1,817 | $5.83 | $10,593.11 |
DisclosureSEC source: 0000950170-24-084407 · ownership.xml · nonDerivative · entry 2 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,256 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| June 30, 2024 Filed Jul 17, 2024 23:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 722 | $3.09 | $2,230.98 |
DisclosureSEC source: 0000950170-24-084407 · ownership.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,073 F1 · kind: Shares acquired through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062065 · ownership.xml · derivative · entry 2 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062065 · ownership.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,351 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| March 27, 2024 Filed Mar 30, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 17,084 | $4.63 | $79,098.92 |
DisclosureSEC source: 0000950170-24-038816 · ownership.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,351 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| February 04, 2024 Filed Feb 5, 2024 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 15,290 | $3.27 | $49,998.30 |
DisclosureSEC source: 0001209191-24-002740 · doc4.xml · nonDerivative · entry 2 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,435 F2 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on February 4, 2024. Read SEC document |
| December 31, 2023 Filed Feb 5, 2024 11:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 711 | $3.09 | $2,196.99 |
DisclosureSEC source: 0001209191-24-002740 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,145 F1 · kind: Includes 711 shares of common stock purchased under the Company's Employee Stock Purchase Plan on December 31, 2023 in an exempt transaction. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032730 · doc4.xml · derivative · entry 2 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock, $.01 Par Value · 28,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 23,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032730 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,434 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantRestricted Stock Unit | 210,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032031 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,184 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: 4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. The vesting determination date for this grant is March 27, 2023. Read SEC document |
| May 15, 2023 Filed May 15, 2023 21:01 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock,$.01 par value | 14,184 | $4.23 | $59,998.32 |
DisclosureSEC source: 0001209191-23-029518 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,184 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on May 13, 2023. Read SEC document |
| September 03, 2022 Filed Sep 7, 2022 08:00 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 1,511 | $0.40 | $601.38 |
DisclosureSEC source: 0001209191-22-048948 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 F1 · shares: Reflects the number of shares of the issuers Common Stock that were withheld to cover tax liability in connection with vesting and settlement of restricted stock units reported on a prior Form 4. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 07:21 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 1,511 | $4.38 | $6,618.18 |
DisclosureSEC source: 0001209191-21-055101 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,221 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with vesting and settlement of restricted stock units reported on a prior Form 4. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 18:36 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 11,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018360 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,732 F1 · shares: Award of restricted stock units, each representing a contingent right to one share of common stock which, subject to continued service, vests in installments of 40%, 20%, and 40% at 6 months, 12 months, and 18 months, respectively, after the grant date. F2 · balance_after: Holdings were adjusted to reflect the issuer's 1-for-6 reverse stock split effected on December 31, 2020. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 08:35 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 3,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051241 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,639 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 07:51 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 1,513 | $1.60 | $2,421.10 |
DisclosureSEC source: 0001209191-19-058938 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,624 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $1.53 to $1.68 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 08:15 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001209191-19-055907 · doc4.xml · derivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-11-07 F1 · derivative.exercise_date: Options issued under the issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to the options vest in equal quarterly installments over two years beginning on November 7, 2019 with the first quarterly installment vesting on February 7, 2020. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 16:23 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 15,075 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001209191-19-018797 · doc4.xml · derivative · entry 2 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,075 Underlying: Common Stock · 15,075 shares Expires 2029-03-08 F2 · derivative.exercise_date: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019 with the first quarterly installment vesting on April 1, 2019. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 16:23 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 9,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-018797 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,137 F1 · shares: Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2019, December 1, 2020, December 1, 2021 and December 1, 2022. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 16:19 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 761 | $13.18 | $10,028.23 |
DisclosureSEC source: 0001209191-19-012975 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,092 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were sold to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $12.9615 to $13.1800 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 22, 2018 Filed Dec 27, 2018 08:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064143 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,853 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 08:31 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 4,119 | $20.66 | $85,080.83 |
DisclosureSEC source: 0001209191-18-061113 · doc4.xml · nonDerivative · entry 2 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,568 F3 · shares: Sales pursuant to a 10b5-1 plan. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.2500 to $20.7900 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 08:31 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 1,072 | $20.20 | $21,655.69 |
DisclosureSEC source: 0001209191-18-061113 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,687 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.0600 to $20.2500 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 16:11 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 747 | $20.28 | $15,149.16 |
DisclosureSEC source: 0001209191-18-057559 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,759 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 16:19 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-050637 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,506 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| June 28, 2018 Filed Jul 2, 2018 07:52 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 5,859 | $27.84 | $163,139.75 |
DisclosureSEC source: 0001209191-18-040132 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,306 F1 · shares: Sales pursuant to a 10b5-1 plan. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $27.45 to $28.15 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 28, 2018 Filed Dec 21, 2018 17:17 UTC Amendment | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 3,774 | $27.84 | $105,068.16 |
DisclosureSEC source: 0001209191-18-063965 · doc4a.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,391 F1 · shares: On July 2, 2018, the reporting person filed a Form 4 reporting the June 28, 2018 sale of 5,859 shares of common stock pursuant to a Rule 10b5-1 plan. The report person's broker subsequently acknowledged that of the 5,859 shares, 2,085 were erroneously sold by the broker. The sale of the 2,085 shares was unwound through the broker's error account and therefore did not occur for purposes of the reporting person's account. This Form 4 amends and restates, in its entirety, the transaction reported in the July 2, 2018 Form 4 in order to correctly report the disposition of 3,774 shares of the issuer's common stock pursuant to the reporting person's Rule 10b5-1 plan. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $27.45 to $28.15 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F1 · balance_after: On July 2, 2018, the reporting person filed a Form 4 reporting the June 28, 2018 sale of 5,859 shares of common stock pursuant to a Rule 10b5-1 plan. The report person's broker subsequently acknowledged that of the 5,859 shares, 2,085 were erroneously sold by the broker. The sale of the 2,085 shares was unwound through the broker's error account and therefore did not occur for purposes of the reporting person's account. This Form 4 amends and restates, in its entirety, the transaction reported in the July 2, 2018 Form 4 in order to correctly report the disposition of 3,774 shares of the issuer's common stock pursuant to the reporting person's Rule 10b5-1 plan. F3 · balance_after: As a result of the overstatement of the number of shares sold on the reporting person's July 2, 2018 Form 4, the reporting person's subsequently filed Form 4s have understated her ownership of the issuer's common stock by 2,085 shares. As of the date of this amendment, the reporting person directly holds 3,653 shares of the issuer's common stock. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 07:40 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,375 | $0.00 Strike: $16.50 | $0.00 |
DisclosureSEC source: 0001209191-18-037138 · doc4.xml · derivative · entry 3 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,625 Underlying: Common Stock · 24,375 shares Expires 2027-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sale pursuant to a 10b5-1 plan. F2 · derivative.exercise_date: The shares subject to this option vest over two years from the May 1, 2017 grant date, with the first 25% having vested at the end of six months after the grant date and the remaining 75% vesting in equal quarterly installments over the remainder of such two year period. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 07:40 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 24,375 | $35.00 | $853,125.00 |
DisclosureSEC source: 0001209191-18-037138 · doc4.xml · nonDerivative · entry 2 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,165 F1 · shares: Exercise and sale pursuant to a 10b5-1 plan. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 07:40 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 24,375 | $16.50 | $402,187.50 |
DisclosureSEC source: 0001209191-18-037138 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sale pursuant to a 10b5-1 plan. Read SEC document |
| May 18, 2018 Filed May 22, 2018 16:35 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 7,288 | $23.67 | $172,470.52 |
DisclosureSEC source: 0001209191-18-032315 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,165 F1 · shares: Sales pursuant to a 10b5-1 plan. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $23.45 to $24.15 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 08:36 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 2,085 | $25.65 | $53,480.25 |
DisclosureSEC source: 0001209191-18-018701 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,453 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 08:37 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 5,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013211 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,538 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 07:44 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 1,670 | $20.53 | $34,288.94 |
DisclosureSEC source: 0001209191-17-063698 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,679 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.20 to $20.85 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 01, 2017 Filed May 3, 2017 16:20 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $16.50 | $0.00 |
DisclosureSEC source: 0001209191-17-029656 · doc4.xml · derivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-05-01 F1 · derivative.exercise_date: The shares subject to this option vest over two years from the May 1, 2017 grant date, with the first 25% to vest at the end of six months after the grant date and the remaining 75% to vest in equal quarterly installments over the remainder of such two year period. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:36 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $27.48 | $0.00 |
DisclosureSEC source: 0001209191-17-017615 · doc4.xml · derivative · entry 2 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-03-01 F2 · derivative.exercise_date: The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2017 with the first quarterly installment vesting on April 1, 2017. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:36 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-017615 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,349 F1 · shares: Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2017, December 1, 2018, December 1, 2019 and December 1, 2020. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 17:14 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 2,429 | $20.74 | $50,381.10 |
DisclosureSEC source: 0001209191-16-153410 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,949 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.30 to $21.15 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.